Ebola: New drug trial aims to halve contaminated contacts

A novel treatment to prevent Ebola infection is entering a clinical trial phase, offering new hope in combating the deadly virus. French researcher Marie Jaspard is spearheading the innovative trial for a drug designed to stop the Bundibugyo virus from causing illness in individuals who have been exposed.

The Bundibugyo virus was responsible for a past epidemic in the Democratic Republic of Congo. This new drug aims to prevent the disease from developing in those who come into contact with the virus. If successful, it could significantly reduce the spread of infection by potentially halving the number of contaminated contacts.

The clinical trial represents a significant step forward in Ebola prevention strategies. By focusing on post-exposure intervention, the treatment could offer a crucial tool for public health officials working to contain outbreaks and protect vulnerable populations.